801 related articles for article (PubMed ID: 17713976)
21. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.
Hu P; Yin Q; Deckert F; Jiang J; Liu D; Kjems L; Dole WP; He YL
J Clin Pharmacol; 2009 Jan; 49(1):39-49. PubMed ID: 18832295
[TBL] [Abstract][Full Text] [Related]
23. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.
He YL; Paladini S; Sabia H; Campestrini J; Zhang Y; Leon S; Ligueros-Saylan M; Jarugula V
Int J Clin Pharmacol Ther; 2008 May; 46(5):259-67. PubMed ID: 18538112
[TBL] [Abstract][Full Text] [Related]
24. Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combination of vildagliptin and metformin in Japanese healthy subjects.
Mita S; Chitnis SD; Kulmatycki K; Salunke A; He YL; Zhou W; Suzuki H
Int J Clin Pharmacol Ther; 2016 Apr; 54(4):305-14. PubMed ID: 26932305
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment.
He YL; Kulmatycki K; Zhang Y; Zhou W; Reynolds C; Ligueros-Saylan M; Taylor A
Int J Clin Pharmacol Ther; 2013 Sep; 51(9):693-703. PubMed ID: 23782585
[TBL] [Abstract][Full Text] [Related]
27. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
Ahrén B; Foley JE; Bosi E
Diabetes Obes Metab; 2011 Mar; 13(3):193-203. PubMed ID: 21205107
[TBL] [Abstract][Full Text] [Related]
28. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.
He YL; Sabo R; Campestrini J; Wang Y; Riviere GJ; Nielsen JC; Rosenberg M; Ligueros-Saylan M; Howard D; Dole WP
Br J Clin Pharmacol; 2008 Mar; 65(3):338-46. PubMed ID: 17961192
[TBL] [Abstract][Full Text] [Related]
29. Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff.
Koyama A; Komori K; Otsuka R; Kajikuri J; Itoh T
J Vasc Surg; 2016 May; 63(5):1360-70. PubMed ID: 25656593
[TBL] [Abstract][Full Text] [Related]
30. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetic model of human insulin following different routes of administration.
Potocka E; Baughman RA; Derendorf H
J Clin Pharmacol; 2011 Jul; 51(7):1015-24. PubMed ID: 20940337
[TBL] [Abstract][Full Text] [Related]
32. Hepatic Dipeptidyl Peptidase-4 Controls Pharmacokinetics of Vildagliptin In Vivo.
Asakura M; Fukami T; Nakajima M; Fujii H; Atsuda K; Itoh T; Fujiwara R
Drug Metab Dispos; 2017 Feb; 45(2):237-245. PubMed ID: 27895112
[TBL] [Abstract][Full Text] [Related]
33. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Brindley C; Short T
Clin Ther; 2003 Oct; 25(10):2553-63. PubMed ID: 14667956
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
He YL; Wang Y; Bullock JM; Deacon CF; Holst JJ; Dunning BE; Ligueros-Saylan M; Foley JE
J Clin Pharmacol; 2007 May; 47(5):633-41. PubMed ID: 17442688
[TBL] [Abstract][Full Text] [Related]
35. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
36. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.
Hoste J; Daci E; Mathieu C
Acta Clin Belg; 2014 Jun; 69(3):171-6. PubMed ID: 24820924
[TBL] [Abstract][Full Text] [Related]
38. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
39. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]